Alfardan Medical with Northwestern Medicine Introduces nSTRIDE: A Revolutionary Non-Surgical Treatment for Joint Pain in Qatar

Alfardan Medical with Northwestern Medicine (AMNM) proudly announces the introduction of nSTRIDE Autologous Protein Solution, an innovative treatment for knee osteoarthritis and joint pain, reinforcing its commitment to delivering advanced and patient-centric healthcare solutions in Qatar.

nSTRIDE is a groundbreaking regenerative therapy designed to alleviate joint pain and improve mobility by leveraging the body’s own healing mechanisms. The treatment involves extracting a small sample of the patient’s blood, processing it to concentrate anti-inflammatory proteins and growth factors, and then injecting the solution into the affected joint. This targeted approach aims to reduce inflammation, slow cartilage degradation, and promote long-term joint health.

The introduction of nSTRIDE at AMNM underscores the organization’s dedication to bringing world-class medical innovations to Qatar, providing patients with access to non-surgical, evidence-based treatment options for osteoarthritis and joint-related conditions.

Dr. Khalil Achkar, Consultant Orthopedist at AMNM, stated: “We are excited to introduce nSTRIDE as a pioneering treatment for joint pain. By offering regenerative medicine solutions, AMNM continues to lead in personalized and cutting-edge healthcare, ensuring that our patients receive the best possible care with minimal downtime.”

AMNM’s introduction of nSTRIDE aligns with its mission to enhance healthcare standards by integrating the latest medical technologies with the expertise of globally renowned specialists. This milestone further solidifies its position as a region's regenerative medicine leader.

Patients experiencing chronic knee pain or early to moderate osteoarthritis are encouraged to consult with AMNM specialists to determine if nSTRIDE is the proper treatment for them.